➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Express Scripts
AstraZeneca
Baxter
McKinsey

Last Updated: July 7, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,579,367

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,579,367
Title:C-terminally tethered amino acids and their fibrinolytic therapeutic uses
Abstract: The present disclosure provides a C-terminal tethered amino acid for modulating the thrombolytic, fibrinolytic and/or anticoagulant properties of a coagulation protein. The present disclosure also provides a coagulation protein having a catalytic site modified, either at the histidine or serine residue, with the C-terminal tethered amino acid as well as therapeutic applications of those modified coagulation proteins.
Inventor(s): Pryzdial; Ed (Vancouver, CA)
Assignee: Canadian Blood Services (Ottawa, CA)
Application Number:14/303,101
Patent Claims:1. An isolated and modified blood coagulation protein, said blood coagulation protein being from the vitamin K-dependent family and having a modified histidine (His) or serine (Ser) residue of the following formula: ##STR00045## wherein: (aa) is lysine or alanine, PEG is 2-8 linear repeating units having the following formula ##STR00046## where each carbon atom of said unit is optionally substituted, His/Ser is a histidine residue or a serine residue of the blood coagulation protein located within a serine protease active site, said His/Ser is covalently linked to the CH.sub.2 moiety by the catalytic site imidazole-nitrogen atom of said histidine or hydroxyl of said serine; R is H or a residue of a natural or non-natural amino acid, n is an integer ranging from 2 to 4; and Y' is ##STR00047## wherein the blood coagulation protein is further defined as Factor Xa or Factor IIa.

2. The isolated and modified blood coagulation protein of claim 1, wherein the blood coagulation protein is a human protein.

3. The isolated and modified blood coagulation protein of claim 1, wherein the blood coagulation protein is isolated from blood or a blood derivative.

4. The isolated modified blood coagulation protein of claim 1, wherein the blood coagulation protein is a Factor Xa (FXa) protein.

5. The isolated and modified blood coagulation protein of claim 4, wherein the FXa protein has (i) a light chain having an amino acid sequence as set forth at positions between 41 to 179 of SEQ ID NO:1 or 2 and (ii) a heavy chain having an amino acid sequence as set forth at positions between 235 to 467, between 235 to 469, between 235 to 473, between 235 to 475, between 235 to 487, or between 235 to 488 of SEQ ID NO: 1 or 2.

6. A combination of a plurality of isolated and modified blood coagulation protein as defined in claim 5 comprising: at least one isolated and modified FXa having, as a heavy chain, an amino acid sequence as set forth at positions between 235 to 487 or between 235 to 488 of SEQ ID NO: 1 or 2; at least one isolated and modified FXa having, as a heavy chain, an amino acid sequence as set forth at positions between 235 to 467, between 235 to 473 or between 235 to 475 of SEQ ID NO: 1 or 2; and at least one isolated and modified FXa having, as a heavy chain, an amino acid sequence as set forth at positions between 235 to 469 of SEQ ID NO: 1 or 2.

7. A method for dissolving a clot in a subject in need thereof, said method comprising administering a therapeutic effective amount of the isolated modified blood coagulation protein of claim 1 to the subject so as to dissolve the clot.

8. A method of improving the therapeutic property of a thrombolytic agent in a subject in need thereof, said method comprising administering a therapeutic effective amount of the isolated modified blood coagulation protein of claim 1 with the thrombolytic agent to the subject.

9. The method of claim 8, wherein the thrombolytic agent is administered at a dose considered sub-therapeutic when used in the absence of the pharmaceutical composition.

10. The method of claim 8, wherein the thrombolytic agent is administered at a timing considered sub-therapeutic when used in the absence of the pharmaceutical composition.

11. The method of claim 8, wherein the thrombolytic agent is selected from the group consisting of tissue plasminogen activator, a modified tissue plasminogen activator, urokinase and streptokinase.

12. The method of claim 11, wherein the modified tissue plasminogen activator is tenecteplase.

13. The isolated and modified blood coagulation protein of claim 1, wherein the (aa) is a natural amino acid.

14. The isolated and modified blood coagulation protein of claim 1, wherein the (aa) is lysine.

15. The isolated and modified blood coagulation protein of claim 1, wherein the (aa) is alanine.

16. The isolated and modified blood coagulation protein of claim 1, wherein the PEG is --(CH.sub.2--CH.sub.2--O--).sub.2-8.

17. The isolated and modified blood coagulation protein of claim 16, wherein the PEG is --(CH.sub.2--CH.sub.2--O--).sub.4-8.

18. The isolated and modified blood coagulation protein of claim 16, wherein the PEG is --(CH.sub.2--CH.sub.2--O--).sub.4.

19. The isolated modified blood coagulation protein of claim 1, wherein the blood coagulation protein is a Factor IIa (FIIa) protein.

Details for Patent 9,579,367

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Microbix Biosystems KINLYTIC urokinase INJECTABLE;INJECTION 021846 001 1978-01-16   Start Trial Canadian Blood Services (Ottawa, CA) 2033-06-13 DISCN search
Microbix Biosystems KINLYTIC urokinase INJECTABLE;INJECTION 021846 002 1978-01-16   Start Trial Canadian Blood Services (Ottawa, CA) 2033-06-13 DISCN search
Microbix Biosystems KINLYTIC urokinase INJECTABLE;INJECTION 021846 003 1978-01-16   Start Trial Canadian Blood Services (Ottawa, CA) 2033-06-13 DISCN search
Genentech TNKASE tenecteplase VIAL 103909 001 2000-06-02   Start Trial Canadian Blood Services (Ottawa, CA) 2033-06-13 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Express Scripts
Dow
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.